Modaresi Seyed Mohamad Sadegh, Becanova Jitka, Vojta Simon, Ryu Sangwoo, Kaye Emily M, Agudelo Juliana, Diolintzi Anastasia, Skende Olga, Storch Judith, Fischer Fabian C, Slitt Angela
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Graduate School of Oceanography, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Chem Res Toxicol. 2025 Sep 15;38(9):1576-1584. doi: 10.1021/acs.chemrestox.5c00199. Epub 2025 Aug 19.
Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant in the per- and polyfluoroalkyl substances (PFAS) class, known to accumulate in the liver and trigger hepatotoxicity. While studies suggested that fatty acid-binding proteins (FABPs) drive the hepatic accumulation of PFAS, evidence is entirely lacking. Using wild-type and mice with global deletion of liver-type and intestine-type FABP (L-FABP, I-FABP), we measured PFOS toxicokinetics by administering single oral doses (0.1, 0.5, and 5 mg/kg) and tracking blood and excreta levels for 65 days. PFOS levels in various tissues were measured at test end. Additionally, we measured PFAS binding to liver tissues from wild-type and FABP knockout mice. Contrary to previous findings, FABP deletion did not significantly alter PFOS blood concentrations, tissue distribution, or elimination rates. Elimination half-lives, clearances, and volumes of distribution were consistent across genotypes, suggesting that neither L-FABP nor I-FABP are critical drivers for PFOS toxicokinetics. binding assays showed similar liver partition coefficients between wild-type and knockout livers for 15 of 19 PFAS, with small differences for some sulfonamides and fluorotelomer sulfonates. These results challenge the presumed role of L-FABP and/or I-FABP in PFAS toxicokinetics, highlighting the need to explore alternative toxicokinetic mechanisms─such as phospholipid binding and transporter-mediated uptake─driving PFAS distribution and elimination.
全氟辛烷磺酸(PFOS)是一种持久性环境污染物,属于全氟和多氟烷基物质(PFAS)类别,已知会在肝脏中蓄积并引发肝毒性。虽然有研究表明脂肪酸结合蛋白(FABP)会促使PFAS在肝脏中蓄积,但完全缺乏相关证据。我们使用野生型小鼠以及肝脏型和肠道型FABP(L-FABP、I-FABP)整体缺失的小鼠,通过单次口服给药(0.1、0.5和5 mg/kg)并追踪65天内的血液和排泄物水平,来测量PFOS的毒代动力学。在试验结束时测量各个组织中的PFOS水平。此外,我们还测量了PFAS与野生型和FABP基因敲除小鼠肝脏组织的结合情况。与之前的研究结果相反,FABP缺失并未显著改变PFOS的血液浓度、组织分布或消除速率。消除半衰期、清除率和分布容积在不同基因型之间是一致的,这表明L-FABP和I-FABP都不是PFOS毒代动力学的关键驱动因素。结合试验表明,19种PFAS中有15种在野生型和基因敲除小鼠肝脏中的分配系数相似,某些磺酰胺和氟调聚物磺酸盐存在微小差异。这些结果对L-FABP和/或I-FABP在PFAS毒代动力学中所假定的作用提出了挑战,突出了探索替代毒代动力学机制(如磷脂结合和转运体介导的摄取)以推动PFAS分布和消除的必要性。